六项随机试验中RAS野生型转移性结直肠癌患者原发肿瘤部位的预后与预测价值
这项回顾性分析纳入六项随机试验中不可切除RAS野生型转移性结直肠癌患者,比较化疗联合EGFR抗体与化疗或化疗联合贝伐珠单抗。汇总分析显示右半肿瘤患者总生存、无进展生存和客观缓解率均更差,肿瘤部位对化疗联合EGFR抗体治疗的获益具有预测作用,左半肿瘤患者获益更大。
要点
- 右半RAS野生型转移性结直肠癌患者的总生存、无进展生存和客观缓解率均劣于左半肿瘤患者。
- 左半肿瘤患者化疗联合EGFR抗体治疗较对照显著改善总生存和无进展生存,右半肿瘤患者无显著获益。
- 肿瘤部位与治疗交互作用对总生存和无进展生存显著,对客观缓解率仅为趋势。
核心结论
- 在RAS野生型转移性结直肠癌患者中,右半肿瘤患者的总生存、无进展生存和客观缓解率均劣于左半肿瘤患者,肿瘤部位具有预后价值。
- 肿瘤部位对化疗联合EGFR抗体治疗较化疗或化疗联合贝伐珠单抗的疗效具有预测作用,左半肿瘤患者获益最大。
- 由于分析为回顾性、基于试验中亚人群且无研究设计完整治疗序列策略,这些预测性结果应谨慎解读。
研究设计与样本
- 回顾性分析六项随机试验(CRYSTAL、FIRE-3、CALGB 80405、PRIME、PEAK和20050181)中不可切除RAS野生型转移性结直肠癌患者。
- 比较化疗联合EGFR抗体治疗(试验组)与化疗或化疗联合贝伐珠单抗(对照组)。
- 5760例随机患者中2159例(37.5%)有原发肿瘤部位和RAS突变状态数据,其中右半515例、左半1644例。
- 通过汇总各研究风险比(HR)和比值比(OR)评估预后价值,通过汇总治疗效应与肿瘤部位的交互作用评估预测价值。
主要发现
- 汇总对照组中,右半 vs 左半肿瘤患者总生存HR=2.03(95%CI 1.69-2.42),无进展生存HR=1.59(95%CI 1.34-1.88),客观缓解率OR=0.38(95%CI 0.28-0.50)。
- 汇总试验组中,右半 vs 左半肿瘤患者总生存HR=1.38(95%CI 1.17-1.63),无进展生存HR=1.25(95%CI 1.06-1.47),客观缓解率OR=0.56(95%CI 0.43-0.73)。
- 左半肿瘤患者化疗联合EGFR抗体治疗较对照显著改善总生存(HR=0.75,95%CI 0.67-0.84)和无进展生存(HR=0.78,95%CI 0.70-0.87)。
- 右半肿瘤患者化疗联合EGFR抗体治疗较对照无显著获益:总生存HR=1.12(95%CI 0.87-1.45),无进展生存HR=1.12(95%CI 0.87-1.44);交互作用P值分别为<0.001和0.002。
- 客观缓解率方面,左半肿瘤患者OR=2.12(95%CI 1.77-2.55),右半肿瘤患者OR=1.47(95%CI 0.94-2.29),交互作用P=0.07。
局限性
- 分析为回顾性 nature,原文写明应谨慎解读预测性结果。
- 分析基于试验纳入患者的亚人群,非全部随机人群。
- 六项研究均未设计完整的治疗序列策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is increasing evidence that metastatic colorectal cancer (mCRC) is a genetically heterogeneous disease and that tumours arising from different sides of the colon (left versus right) have different clinical outcomes. Furthermore, previous analyses comparing the activity of different classes of targeted agents in patients with KRAS wild-type (wt) or RAS wt mCRC suggest that primary tumour location (side), might be both prognostic and predictive for clinical outcome. METHODS: This retrospective analysis investigated the prognostic and predictive influence of the localization of the primary tumour in patients with unresectable RAS wt mCRC included in six randomized trials (CRYSTAL, FIRE-3, CALGB 80405, PRIME, PEAK and 20050181), comparing chemotherapy plus EGFR antibody therapy (experimental arm) with chemotherapy or chemotherapy and bevacizumab (control arms). Hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) for patients with left-sided versus right-sided tumours, and odds ratios (ORs) for objective response rate (ORR) were estimated by pooling individual study HRs/ORs. The predictive value was evaluated by pooling study interaction between treatment effect and tumour side. RESULTS: Primary tumour location and RAS mutation status were available for 2159 of the 5760 patients (37.5%) randomized across the 6 trials, 515 right-sided and 1644 left-sided. A significantly worse prognosis was observed for patients with right-sided tumours compared with those with left-sided tumours in both the pooled control and experimental arms for OS [HRs = 2.03 (95% CI: 1.69-2.42) and 1.38 (1.17-1.63), respectively], PFS [HRs = 1.59 (1.34-1.88) and 1.25 (1.06-1.47)], and ORR [ORs = 0.38 (0.28-0.50) and 0.56 (0.43-0.73)]. In terms of a predictive effect, a significant benefit for chemotherapy plus EGFR antibody therapy was observed in patients with left-sided tumours [HRs = 0.75 (0.67-0.84) and 0.78 (0.70-0.87) for OS and PFS, respectively] compared with no significant benefit for those with right-sided tumours [HRs = 1.12 (0.87-1.45) and 1.12 (0.87-1.44) for OS and PFS, respectively; P value for interaction <0.001 and 0.002, respectively]. For ORR, there was a trend (P value for interaction = 0.07) towards a greater benefit for chemotherapy plus EGFR antibody therapy in the patients with left-sided tumours [OR = 2.12 (1.77-2.55)] compared with those with right-sided tumours [OR = 1.47 (0.94-2.29)]. Exclusion of the unique phase II trial or the unique second-line trial had no impact on the results. The predictive effect on PFS may depend of the type of EGFR antibody therapy and on the presence or absence of bevacizumab in the control arm. CONCLUSION: This pooled analysis showed a worse prognosis for OS, PFS and ORR for patients with right-sided tumours compared with those with left-sided tumours in patients with RAS wt mCRC and a predictive effect of tumour side, with a greater effect of chemotherapy plus EGFR antibody therapy compared with chemotherapy or chemotherapy and bevacizumab, the effect being greatest in patients with left-sided tumours. These predictive results should be interpreted with caution due to the retrospective nature of the analysis, which was carried out on subpopulations of patients included in these trials, and because none of these studies contemplated a full treatment sequence strategy.
引用
- Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017. PMID: 28407110. doi:10.1093/annonc/mdx175
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。